 Aprea Therapeutics Inc NASDAQ: APRE presented data at the European Society of Medical Oncology ESMO Congress 2021 from its Phase 12 trial in advanced solid tumors. The trial is evaluating the safety and efficacy of eprenetapopt in combination with pembrolizumab. 